Health officials and local researchers have launched an emergency vaccination campaign to stem an outbreak of ceftriaxone-resistant typhoid in Hyderabad, Pakistan. The outbreak has sickened more than 800 people since it began in late 2016.
Geneva, Switzerland – January 3, 2018 – A typhoid conjugate vaccine has been prequalified by the World Health Organization (WHO), bringing the vaccine one step closer to reaching millions more people at risk of typhoid.
This week immunization experts from around the world will gather in Geneva to review new evidence and discuss recommendations for WHO immunization policy. An important item on the agenda for the fall meeting is typhoid vaccines. A recommendation on the use of new typhoid conjugate vaccines (TCVs) could significantly impact the effort to reduce the global burden of typhoid, a disease that impacts nearly 12 million people a year.
In South Asia, where the burden of enteric fever is thought to be highest, most typhoid studies have focused on urban areas. As a result, researchers have been unsure how well available data could be extrapolated to predominantly rural areas.
New typhoid conjugate vaccines offer important advantages over prior vaccines, including the ability to protect young children, longer lasting protection, and the potential to be a part of routine immunization of infants.
Investigators from the Aga Khan University (AKU) are actively investigating a large outbreak of typhoid fever bacteria that are resistant to ceftriaxone, an antibiotic commonly used by physicians to treat this infection.
This is Gul Rahim’s story of typhoid, as told to Attaullah Baig of Aga Khan University Hospital on January 7, 2017, and translated into English. The interview was conducted in Urdu and has been edited for clarity and length.